Biology

New Immune-Boosting Pet Supplement May Add Years to the Life of Your Pet

Friday, November 22, 2019 - 5:44am

"We wanted to create a product that would help pets stay healthy and active for years to come.

Key Points: 
  • "We wanted to create a product that would help pets stay healthy and active for years to come.
  • "It is the responsibility of the pet owner to do everything possible to minimize the risk of cancer in their pets.
  • "Giving your pets a high-quality antioxidant supplement is highly recommended to further reduce the risk of cancer."
  • Kamalski, who has decades of experience in the natural health supplement industry, decided to develop this all-natural supplement when his 12-year-old dog, Sienna, developed bone cancer.

Universal Sequencing Technology Launches the TELL-Seq™ WGS Library Prep Kit for Long-Read DNA Sequencing

Thursday, November 21, 2019 - 3:00pm

CANTON, Mass., Nov. 21, 2019 /PRNewswire-PRWeb/ --Universal Sequencing Technology Corporation ('UST'), a developer of Next Generation Sequencing (NGS) technologies, today emerges from stealth mode, unveiling its TELL-Seq technology for linked, long-read DNA sequencing applications.

Key Points: 
  • CANTON, Mass., Nov. 21, 2019 /PRNewswire-PRWeb/ --Universal Sequencing Technology Corporation ('UST'), a developer of Next Generation Sequencing (NGS) technologies, today emerges from stealth mode, unveiling its TELL-Seq technology for linked, long-read DNA sequencing applications.
  • The TELL-Seq WGS Library Preparation kit tags segments of DNA through molecular barcoding, maintaining the original structure, i.e.
  • Universal Sequencing Technology was founded by next generation DNA sequencing veterans from Roche/454 and is rapidly building out their R&D, operations and commercial teams.
  • Currently, UST has filed a total of 19 patent applications covering linked, long-read library preparation chemistry and groundbreaking 3rd generation DNA sequencing technology.

New research casts doubt on near reality of 'designer babies'

Thursday, November 21, 2019 - 5:26pm

However, there has been no research published to indicate the potential success of polygenic embryo selection.

Key Points: 
  • However, there has been no research published to indicate the potential success of polygenic embryo selection.
  • "Through our research, we can confidently say that trait predictions for embryos based on polygenic scores are not very accurate."
  • The research team hopes that this work will promote an open and evidence-based discussion of these aspects among the public and policymakers.
  • The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York.

The Pod by Eight Sleep Named to TIME's List of the 100 Best Inventions of 2019

Thursday, November 21, 2019 - 4:28pm

NEW YORK, Nov. 21, 2019 /PRNewswire/ --Today, TIME revealed the Pod by Eight Sleep has been selected as one of TIME's 2019 Best Inventions.

Key Points: 
  • NEW YORK, Nov. 21, 2019 /PRNewswire/ --Today, TIME revealed the Pod by Eight Sleep has been selected as one of TIME's 2019 Best Inventions.
  • The annual list features the 100best inventions that are making the world better, smarter and even a bit more fun.
  • The Pod is the latest innovation by Eight Sleep, the sleep fitness company using technology to help people sleep better.
  • See the full list here: time.com/bestinventions2019
    Eight Sleep is the world's first sleep fitness brand with a mission to fuel human potential through optimal sleep.

Global Pheromones Market in Agriculture by Crop Type, Function, Mode of Application, Type, and Region - Forecast to 2025 - ResearchAndMarkets.com

Thursday, November 21, 2019 - 5:52pm

The global pheromones market size is estimated to be valued at USD 2.4 billion in 2019 and is projected to reach USD 5.7 billion by 2025, recording a CAGR of 15.3%.

Key Points: 
  • The global pheromones market size is estimated to be valued at USD 2.4 billion in 2019 and is projected to reach USD 5.7 billion by 2025, recording a CAGR of 15.3%.
  • This report segments the seed market based on type, crop type, function, mode of application, and region.
  • By type, the pheromones industry is categorized as sex pheromones, aggregation pheromones, and others, which include alarm pheromones, trail pheromones, and host marking pheromones.
  • North America is estimated to account for the largest market share in the pheromones market.

Companies Strive to Tackle Ocular Diseases as Rates of Incidences Grow

Thursday, November 21, 2019 - 2:00pm

Generally, the market growth can be primarily attributed to the increased funding by regulatory bodies for conducting research on ocular disorders.

Key Points: 
  • Generally, the market growth can be primarily attributed to the increased funding by regulatory bodies for conducting research on ocular disorders.
  • In addition, technological advancements and increasing strategic collaborations are some of the other factors expected to drive the market for retinal disorder treatments.
  • MANF Therapeutics is the front-runner and primary worldwide intellectual property (IP) holder for MANF-based therapies including protein therapy, gene therapy and cell therapy.
  • Further applications for MANF may include Alzheimer's disease, traumatic brain injury, myocardial infarction, antibiotic-induced ototoxicity and certain other orphan diseases.

Companies Strive to Tackle Ocular Diseases as Rates of Incidences Grow

Thursday, November 21, 2019 - 2:00pm

Generally, the market growth can be primarily attributed to the increased funding by regulatory bodies for conducting research on ocular disorders.

Key Points: 
  • Generally, the market growth can be primarily attributed to the increased funding by regulatory bodies for conducting research on ocular disorders.
  • In addition, technological advancements and increasing strategic collaborations are some of the other factors expected to drive the market for retinal disorder treatments.
  • MANF Therapeutics is the front-runner and primary worldwide intellectual property (IP) holder for MANF-based therapies including protein therapy, gene therapy and cell therapy.
  • Further applications for MANF may include Alzheimer's disease, traumatic brain injury, myocardial infarction, antibiotic-induced ototoxicity and certain other orphan diseases.

Excision BioTherapeutics Presents Data to Support HIV Cure Using CRISPR Gene Editing Technology

Thursday, November 21, 2019 - 5:00pm

Presentations included Toward HIV Cure: The CRISPR Story,andGene Editing Strategies toward HIV Cure using Non-Human Primates,presented by Drs.

Key Points: 
  • Presentations included Toward HIV Cure: The CRISPR Story,andGene Editing Strategies toward HIV Cure using Non-Human Primates,presented by Drs.
  • Researchers at the Lewis Katz School of Medicine at Temple University (LKSOM) demonstrated the ability to remove HIV genomes from cell lines as well as transgenic mice using CRISPR, a powerful gene editing technology.
  • The scientists at LKSOM, who are associated with Excision BioTherapeutics, were the first to demonstrate a functional cure for HIV in animals.
  • Excision BioTherapeutics has licensed the viral gene editing technology from Temple University, where Dr. Khalili is also employed, for commercial development and clinical trials.Dr.

Beam Therapeutics to Present New Preclinical Data on Base Editing Programs for Hemoglobinopathies at ASH 2019

Thursday, November 21, 2019 - 3:05pm

Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced that it will present preclinical data for the companys programs addressing sickle cell disease and beta thalassemia, two blood disorders that lack effective, disease-modifying treatments, at the 61st Annual American Society of Hematology (ASH) Annual Meeting, being held December 7-10, 2019 in Orlando, Fla.

Key Points: 
  • Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced that it will present preclinical data for the companys programs addressing sickle cell disease and beta thalassemia, two blood disorders that lack effective, disease-modifying treatments, at the 61st Annual American Society of Hematology (ASH) Annual Meeting, being held December 7-10, 2019 in Orlando, Fla.
  • Details of the new data being presented in a poster at ASH are as follows:
    Poster Session: 801 Gene Therapy and Transfer: Poster II
    Beam Therapeutics is developing precision genetic medicines through base editing.
  • Founded by leading scientists in CRISPR gene editing, Beam is pursuing therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA.
  • Beam is headquartered in Cambridge, Massachusetts.

Global DNA Test Kits Market: Size, Share, Growth, Trends, and Forecast (2019-2027) - ResearchAndMarkets.com

Thursday, November 21, 2019 - 2:40pm

This report analyzes the current and future scenario of the global DNA test kits market.

Key Points: 
  • This report analyzes the current and future scenario of the global DNA test kits market.
  • Growing popularity of direct-to-consumer testing and increase in demand for DNA kits for disease risk assessment and health & fitness are the major factors projected to drive the global DNA test kits market during the forecast period.
  • The global DNA test kits market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market.
  • The DNA test kits market in North America is likely to be driven by patient demand for service personalization, especially in the U.S. and increase in the number of DNA test kits providers in the region.